Publisher
Springer Science and Business Media LLC
Reference15 articles.
1. Janssen Pharmaceuticals. BALVERSATM (erdafitinib): US prescribing information. 2019.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf
. Accessed 7 May 2019.
2. Karkera JD, Cardona GM, Bell K, et al. Oncogenic characterization and pharmacologic sensitivity of activating fibroblast growth factor receptor (FGFR) genetic alterations to the selective FGFR inhibitor erdafitinib. Mol Cancer Ther. 2017;16(8):1717–26.
3. Tabernero J, Bahleda R, Dienstmann R, et al. Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2015;33(30):3401–8.
4. FDA. FDA approves first targeted therapy for metastatic bladder cancer [media release]. 12 Apr 2019.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm635906.htm
.
5. Astex Therapeutics. Astex announces new drug discovery alliance with Janssen Pharmaceutica N.V [media release]. 9 Jun 2008.
http://www.astex-therapeutics.com
.
Cited by
104 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献